Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 55.47B 51.13B 48.09B 89.97B 6,000B 90.61B 608B 236B 2,957B 239B 234B 10,248B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 70.54B 65.03B 61.17B 114B 7,630B 115B 774B 300B 3,760B 304B 297B 13,034B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

04-07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
03-31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
03-30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
03-19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
03-04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
11-12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25/09/25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
19/08/25	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
30/06/25	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
12/02/25	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
19/10/24	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
27/08/24	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
27/06/24	Allergan Aesthetics Debuts Alle Payment Plans	CI

01/04/24	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
20/04/22	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
06/04/22	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22/03/22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
10/12/21	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

20/04/21	Planète Bourse : La revue de presse du mardi 20 avril 2021
07/05/20	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
07/05/20	La Chine repart, mais Washington veille
06/05/20	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
06/05/20	Trump franchit le Rubicon

Actavis PLC Share Price NYSE

Stocks

US00507K1034

Pharmaceuticals

Valuation: Actavis PLC

Latest news : Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	30/11/2016
Robert Michael PSD	President	55	07/05/2020

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	07/05/2020
Scott Reents BRD	Director/Board Member	-	07/05/2020
Ryan Quigley BRD	Director/Board Member	-	07/05/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.21%	-5.37%	+39.94%	+145.38%	980B
JOHNSON & JOHNSON	-2.48%	-4.17%	+51.52%	+39.07%	550B
ABBVIE INC.	-2.14%	-3.68%	+16.71%	+56.15%	382B
ROCHE HOLDING AG	-2.18%	+0.25%	+25.86%	+16.53%	317B
ASTRAZENECA PLC	+0.87%	-1.29%	+25.93%	+14.10%	270B
NOVARTIS AG	+0.76%	-2.56%	+24.94%	+30.94%	269B
NOVO NORDISK A/S	+4.86%	+2.44%	-39.75%	-45.65%	191B
AMGEN INC.	-1.19%	-4.65%	+16.56%	+47.00%	182B
GILEAD SCIENCES, INC.	-1.35%	-1.68%	+14.59%	+56.94%	154B
Average	-0.43%	-2.68%	+19.59%	+40.05%	366B
Weighted average by Cap.	-0.94%	-3.38%	+28.36%	+64.16%

	2018	2019
Net sales	15.79B 13.76B 12.68B 11.93B 22.31B 1,488B 22.47B 151B 58.59B 733B 59.26B 57.99B 2,541B	16.09B 14.02B 12.92B 12.15B 22.74B 1,516B 22.9B 154B 59.71B 747B 60.39B 59.1B 2,590B
Net income	-5.1B -4.44B -4.09B -3.85B -7.2B -480B -7.25B -48.7B -18.91B -237B -19.13B -18.72B -820B	-5.27B -4.59B -4.23B -3.98B -7.45B -497B -7.5B -50.37B -19.56B -245B -19.78B -19.36B -849B
Net Debt	21.89B 19.07B 17.58B 16.54B 30.94B 2,063B 31.16B 209B 81.24B 1,017B 82.17B 80.41B 3,524B	17.3B 15.08B 13.9B 13.07B 24.46B 1,631B 24.63B 165B 64.22B 804B 64.95B 63.56B 2,786B

End-of-day quote NYSE Other stock markets
- ^USD	-